Latanoprost is a prostaglandin F2(alpha) analogue. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor.
XALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Published Studies Related to Xalatan (Latanoprost)
Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol. [2011.10]
PURPOSE: To evaluate bimatoprost versus latanoprost and timolol fixed combination (LTFC) over the 24-hour diurnal curve in patients who switched from timolol... CONCLUSIONS: The LTFC and bimatoprost therapies were equally effective in maintaining IOP at lower levels during the 24-hour period in patients who switched from timolol therapy. Adverse events were more frequent with bimatoprost therapy.
A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. [2011.09]
CONCLUSIONS: Taprenepag isopropyl significantly reduces IOP in POAG and ocular hypertension. Taprenepag isopropyl monotherapy is comparable to latanoprost 0.005% in reducing IOP. As demonstrated in this report, the activity of taprenepag isopropyl is additive to that of latanoprost 0.005%. Further studies are required to determine whether it shows similar additivity when administered with other ocular antihypertensive medications.
Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. [2011.08.19]
BACKGROUND: A noninferiority trial was conducted to evaluate the efficacy of a single evening dose of fixed-combination latanoprost 50 mug/mL and timolol 0.5 mg/mL (Xalacom(R); LTFC), in Chinese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who were insufficiently controlled on beta-blocker monotherapy or beta-blocker-based dual therapy... CONCLUSIONS: A single evening dose of LTFC was at least as effective as the unfixed combination of latanoprost in the PM and timolol in the AM in reducing IOP in Chinese subjects with POAG or OH whose IOP was insufficiently reduced with beta-blocker monotherapy or beta-blocker-based dual therapy. LTFC is an effective and well tolerated once-daily treatment for POAG and OH.
The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. [2011.08]
PURPOSE: To compare the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness (CCT)... CONCLUSIONS: Topical therapy with prostaglandin analogues is associated with CCT reduction. Latanoprost, travoprost, and bimatoprost have a similar effect on CCT.
Effect of latanoprost on choroidal blood flow regulation in healthy subjects. [2011.06.22]
PURPOSE: The present study tested the hypothesis that human choroidal blood flow (ChBF) regulation in the face of changes in ocular perfusion pressure (OPP) may be modified by a drug-induced decrease in intraocular pressure (IOP)... CONCLUSIONS: The data indicate that latanoprost improves ChBF regulation during both an increase and a decrease in OPP. Since latanoprost did not affect baseline ChBF, the authors assume that this effect is related to the decrease in IOP. This finding has important implications for understanding the relation between IOP and vascular factors in glaucoma, because it indicates that a reduction in IOP itself improves ChBF regulation.
Clinical Trials Related to Xalatan (Latanoprost)
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH). [Completed]
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in
Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in
efficacy and similarity of safety between Xalacom and Xalatan.
Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma [Recruiting]
Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata [Active, not recruiting]
This is a single center, randomized, investigator-masked study to determine the efficacy and
safety of latanaprost and bimatoprost ophthalmic solutions in promoting eyelash growth in
patients who have lost their eyelashes due to alopecia areata. These medications are
FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer,
darker, and thicker eyelashes with their use. In this study, patients will be asked to apply
these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped
applicator once a day.
Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma [Recruiting]
Intraocular pressure (IOP) is considered to be the main risk factor for progression of
glaucoma and therefore the main target of therapy. Pharmacologic treatment of glaucoma has
changed considerably during the last decades due to the introduction of prostaglandin
analogues. Three of these are commonly used in North America: latanoprost (Latanoprost T,
Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).
There have been several studies to evaluate their effectiveness. The three seem to be
equivalent, according to the only study that has compared the molecules. Latanoprost is
employed initially, due to its paucity of side effects when compared to the other two
analogues. However, if it is not effective, several studies ahve shown that a result is
possible using either travoprost or bimatoprost. No study has been conducted to date
systematically comparing the three molecules in cases of resistance to latanoprost. In
actuality, the investigators patients will receive treatment identical to current practice
with the exception of the group continuing with latanoprost. Several studies confirm the
benefit of changing prostaglandin analogues if the first has not signficantly decreased the
IOP (Palmberg et al. 2004). Each prostaglandin has unique properties which may cause the
mechanism of action to vary slightly among patients. (cf. Pharmacological Aspects)
The goal of the study is thus to evaluate the efficaciousness of latanoprost, bimatoprost
and travoprost in their IOP-lowering capacity in patients who do not initially respond to
Safety Study of Latanoprost Slow Release Insert [Recruiting]
This study is a phase 1, open-label, dose-escalation, safety and tolerability study, which
will be conducted at one study site. This study will include 3 cohorts. Each cohort will
have approximately 5 subjects. Subjects will not be randomized into the study. The first
cohort will receive low dose drug insert, second cohort will receive 2 low dose drug inserts
thus achieving twice the drug levels compared to cohort I and third cohort will receive high
dose drug insert.
Reports of Suspected Xalatan (Latanoprost) Side Effects
Intraocular Pressure Increased (179),
Eye Irritation (75),
Drug Ineffective (62),
Visual Acuity Reduced (59),
Eye Pain (55),
Visual Impairment (52),
Eye Disorder (50),
Death (45), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Xalatan has an overall score of 8. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Xalatan review by 45 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || glaucoma|
|Dosage & duration:|| || 1 drop every night (in 24h) (0,005%) (dosage frequency: once a day) for the period of for the last 10 years|
|Other conditions:|| || none|
|Other drugs taken:|| || Cosopt (dorzolamide Hydrochloride)|
|Benefits:|| || lowering of intraocular pressure /keeping it under control|
|Side effects:|| || A slight change in the coulour of the treated eye. |
|Comments:|| || My juvenile/pigmentary (open angle) glaucoma was diagnosed when I was 26 in 1989 (my mother also had it). I was prescribed 2 kinds of eye drops which were effective for some time, but after a while, they couldn't control the intraocular pressure in my left eye, so I had to undergo a trabeculectomy in 1992.
Now I put drops only in my right eye (Cosopt 2 times a day and Xalatan once a day before I go to sleep). My eye pressure has been under control ever since. |
Page last updated: 2011-12-09